New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:53 EDTMNKDPanel raised questions about Afrezza's commercial outlook, says Piper Jaffray
Piper Jaffray believes the issues discussed as yesterday's FDA panel meeting raise questions regarding the commercial outlook for Afrezza. Piper believes FDA approval of the drug "seems inevitable" with yesterday's positive vote, but it sees challenges ahead and raised its price target for MannKind shares to only $2.00 from $1.50. It keeps an Underweight rating on the stock.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 18, 2014
16:03 EDTMNKDOptions Update; July 18, 2014
Subscribe for More Information
11:47 EDTMNKDStocks with call strike movement; BBRY MNKD
Subscribe for More Information
July 16, 2014
11:53 EDTMNKDStocks with call strike movement; MNKD SUNE
MannKind (MNKD) January 17 call option implied volatility increased 6% to 79, SunEdison (SUNE) October 28 call option implied volatility increased 3% to 58 according to IVolatility.
July 11, 2014
11:33 EDTMNKDStocks with call strike movement; MNKD SUNE
Subscribe for More Information
July 10, 2014
05:48 EDTMNKDStocks with implied volatility movement; CBSO MNKD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use